R & D

NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers^® for the treatment of inflammatory diseases and hematological disorders. The company has pre-clinical Spiegelmers in additional indications. Please click "pipeline" on the left to learn further details about compounds in development.

NOXXON's technology platform is based on a combination of chemical mirroring principles and the screening of extremely large libraries. The technology is covered by a vast patent portfolio giving NOXXON and its partners full freedom to operate. Please click on "technology" in the menu on the left to learn more about the Spiegelmer technology and its advantages over other therapeutic modalities.